Elliott Associates, L.P. is the second biggest holder of CorMedix, Inc. (CRMD)

CorMedix, Inc. (NYSE:CRMD) is on recovery track with 90.37% gain from a 1-year low price of $0.322. The company lost -5.69% to attain the price of $0.61 on 10/6/2017. Throughout the recent session, the prices were hovering between $0.583 and $0.64. These shares are 555.74% off its target price of $4 and the current market capitalization stands at $34.52M. The recent change has given its price a 40.34% lead over SMA 50 and -81.08% deficit over its 52-week high. The stock witnessed 42.19% gains, 50.99% gains and -45.27% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CRMD’s volatility during a week at 19.3% and during a month it has been found around 10.75%.

CorMedix, Inc. (CRMD) Top Holders

Institutional investors currently hold around $9 million or 27.5% in CRMD stock. Look at its top three institutional owners. Sabby Management, Llc owns $2.6 million in CorMedix, Inc., which represents roughly 7.54% of the company’s market cap and approximately 28.91% of the institutional ownership. Similar statistics are true for the second largest owner, Elliott Associates, L.P., which owns 4,166,868 shares of the stock are valued at $2.55 million. The third largest holder is Susquehanna International Group, Llp, which currently holds $1.27 million worth of this stock and that ownership represents nearly 3.67% of its market capitalization.

CorMedix, Inc. 13F Filings

At the end of 06/30/2017 reporting period, 14 institutional holders increased their position in CorMedix, Inc. (NYSE:CRMD) by some 9,962,446 shares, 12 decreased positions by 307,036 and 11 held positions by 4,517,609. That puts total institutional holdings at 14,787,091 shares, according to SEC filings. The stock grabbed 7 new institutional investments totaling 5,080,257 shares while 3 institutional investors sold out their entire positions totaling 64,470 shares.

CorMedix, Inc. (NYSE:CRMD) Insider Trades

Multiple company employees have indulged in significant insider trading. CorMedix, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CEO Baluch Khoso has acquired 36,207 shares of CorMedix, Inc. (CRMD) in trading session dated Aug. 18, 2017. These shares are worth $15,207 and were traded at $0.42 each. The SEC filing shows that Khan Mehmood performed a purchase of 400,000 shares. The Director added these shares by way of transaction on Aug. 18, 2017. The company’s shares were assimilated at $0.39 per share worth to an investment of some $156,000 on account of Khan Mehmood.

Director, Kaplan Myron, purchased 80,000 common shares of CorMedix, Inc. (CRMD) in the open market. In a transaction dated Aug. 17, 2017, the shares were bought at an average price of $0.4, giving away a sum of $32,000. After this purchase, 180,000 common shares of CRMD are directly owned by the insider, with total stake valued at $109,800.

In the transaction dated Aug. 14, 2017, the great number of shares acquired came courtesy the Director; Kaplan Myron added a total of 50,000 shares at an average price of $0.35, amounting to approximately $17,500. The insider now directly owns 100,000 shares worth $61,000.

CorMedix, Inc. (CRMD) Analyst Guide

Not many analysts have released their opinion on CorMedix, Inc. (NYSE:CRMD), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous articleAre Hedge Funds Betting Against Titan Pharmaceuticals, Inc. (TTNP)?
Next articleAn End-of-Day Technical Review: Overstock.com, Inc. (OSTK), Aralez Pharmaceuticals Inc. (ARLZ)